NewsBenzingaClimb BioとMabworks、IgA腎症に対するCLYM116/MIL116の四半期投与を支持する第1相データを報告;第3相試験は2027年に開始予定 Climb BioとMabworks、IgA腎症に対するCLYM116/MIL116の四半期投与を支持する第1相データを報告;第3相試験は2027年に開始予定 Benzinga 2026.10.23 20:01 (GMT+0) Open on Benzinga Other news Wolfe Research Initiates Coverage On Monster Beverage with Outperform Rating Druckenmiller Buys Miners, Warns '27 Could Be 'Disappointing' Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42 Wolfe Research Initiates Coverage On PepsiCo with Peer Perform Rating BTIG Reiterates Neutral on FuboTVto Neutral BTIG Reiterates Buy on MARA Holdings, Maintains $27 Price Target
Wolfe Research Initiates Coverage On Keurig Dr Pepper with Outperform Rating, Announces Price Target of $42